Cargando…
Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
In 2021, policy areas of focus for FDA Oncology included the Accelerated Approval programme, expanding eligibility criteria, dose optimization and patient-reported outcomes. The FDA continued to be active with approvals of both new drugs and supplementary applications, including three new chimeric a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824437/ https://www.ncbi.nlm.nih.gov/pubmed/35136230 http://dx.doi.org/10.1038/s41571-022-00605-5 |